G1 Therapeutics, Inc. Annual Income Tax Expense (Benefit) in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
G1 Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2020 to 2023.
  • G1 Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $0.000, a 100% decline year-over-year.
  • G1 Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $1.81M, a 39.9% decline year-over-year.
  • G1 Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $3.12M, a 83.2% increase from 2022.
  • G1 Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $1.7M, a 83.8% increase from 2021.
  • G1 Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was $925K, a 34.4% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.